藥明系急漲12%-22% 惟開拓及騰盛博藥挫15%-28%
醫藥股今天以藥明系表現最好,尤其是半新股藥明合聯(02268.HK)連升第二天,最高見23元,現報22.85元,急漲22%。藍籌藥明康德(02359.HK)連升第三天,最高見57.9元,現報56.35元,急漲12%;藥明生物(02269.HK)高見21.4元,現報21.05元,回升12%。
來凱醫藥-B(02105.HK)連升第四天,最高見8.7元,現報8.26元,續升14%。康龍化成(03759.HK)挑戰50天線(12.06元)阻力,最高見12.08元,現報11.4元,回升9%。
百濟神州(06160.HK)、聯邦制藥(03933.HK)、神威藥業(02877.HK)、石四藥(02005.HK)、凱萊英(06821.HK)、信達生物(01801.HK)、泰格醫藥(03347.HK)、聖諾醫藥-B(02257.HK)及翰森(03692.HK)升2%-6%,後者最強報14.44元。
然而,騰盛博藥-B(2137.HK)急挫近28%報1.23元。開拓藥業-B(09939.HK)尋底,最低見1.03元,再創上市新低,現報1.11元,急挫15%。科笛-B(02487.HK)跌4.6%報7.63元。藍籌石藥(01093.HK)反覆續跌逾2%報5.96元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.